Metabolites of Pinang Yaki (Areca vestiaria) Fruit Extract: A Metabolite Profiling Study.

Abstract

Background:Pinangyakihas bioactive compoundsthathavepotential as a new herbal supplement.Abetter understanding of the bioactive compounds ofpinangyakiusing untargeted metabolomic profiling studies will provide clearer insight into the health benefits ofpinangyakiandin particular itspotential for the therapy and prevention ofCovid-19. Methods:Fresh samples of pinangyaki( Arecavestiaria) are obtained from forests in North Sulawesi Province, Indonesia. Samples were used for untargeted metabolomics analysis by UPLC-MS. Results:Based on an untargeted metabolomic profiling study ofpinangyaki, 2504 compounds in ESI- and 2645 compounds in ESI+ were successfully obtained. After the analysis, 356 compounds in ESI- and 543 compounds in ESI+ were identified successfully.MajorcompoundsAlpha-Chlorohydrin (PubChem ID: 7290)andTagatose (PubChem ID: 439312)were found in ESI+ andESI-. Discussion:TheTop 10metabolitesfrompinangyakiextract (ESI+) jugahavebeenindicated inpreventingSARS Cov2infectionandhaveexhibitedgood neuroprotective immunity.Benzothiazole (PubChem ID: 7222), L-isoleucine (PubChem ID: 6306), D-glucono-delta-lactone (PubChem ID: 736), Diethylpyrocarbonate (PubChem ID: 3051), Bis(2-Ethylhexyl) amine(PubChem ID: 7791), Cinnamic acid (PubChem ID: 444539), and Trigonelline (PubChem ID: 5570)also had potential effects as an antiviral,anti-inflammatory,and anti-Covid19. Conclusion:Untargetedmetabolomicprofilingshowed many bioactive compounds contained in pinangyaki( Arecavestiaria)extract.The top 10 compounds have been identified andexploredfortheir potential benefits as anti-Covid19 supplement products. This is a preliminary study which still needs further research such as preclinical and clinical trials.